What type of drug is Lumoxiti?
Medically reviewed by Drugs.com. Last updated on Oct 5, 2020.
Lumoxiti is classified as an injectable anti-CD22 (antibody-drug conjugate against CD-22) recombinant immunotoxin
Immunotoxin biologics like Lumoxiti are cancer agents that deliver targeted drug therapy to kill cancer cells. CD22 is a protein that is found in higher amounts in HCL cells compared to healthy B cells, making it a reasonable target for drug treatment.
Lumoxiti (moxetumomab pasudotox-tdfk) from AstraZeneca is a first-in-class treatment for patients with hairy cell leukemia (HCL), a blood cancer that results in excessive production of B cells, a type of white blood cell that appears "hairy" under microscopic examination. It is approved for the treatment of relapsed or refractory HCL in patients who have received at least two prior lines of therapy.
Besponsa (inotuzumab ozogamicin) injection is also CD22-directed antibody-drug conjugate, approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Besponsa is manufactured by Pfizer.